[HTML][HTML] Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment
G Ranieri, I Marech, V Lorusso, V Goffredo… - World Journal of …, 2014 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer in the world.
According to Barcelona Clinic Liver Cancer modified criteria, patients with early stage …
According to Barcelona Clinic Liver Cancer modified criteria, patients with early stage …
[HTML][HTML] Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment
G Ranieri, I Marech, V Lorusso, V Goffredo… - World Journal of …, 2014 - wjgnet.com
Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer in the world.
According to Barcelona Clinic Liver Cancer modified criteria, patients with early stage …
According to Barcelona Clinic Liver Cancer modified criteria, patients with early stage …
[HTML][HTML] Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment.
G Ranieri, I Marech, V Lorusso, V Goffredo… - World Journal of …, 2014 - europepmc.org
Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer in the world.
According to Barcelona Clinic Liver Cancer modified criteria, patients with early stage …
According to Barcelona Clinic Liver Cancer modified criteria, patients with early stage …
[引用][C] Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment
G Ranieri, I Marech, V Lorusso, V Goffredo… - WORLD JOURNAL OF …, 2014 - ricerca.uniba.it
Molecular targeting agents associated with transarterial chemoembolization or radiofrequency
ablation in hepatocarcinoma treatment IRIS IRIS Home Sfoglia Macrotipologie & tipologie …
ablation in hepatocarcinoma treatment IRIS IRIS Home Sfoglia Macrotipologie & tipologie …
Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment
G Ranieri, I Marech, V Lorusso… - World journal of …, 2014 - pubmed.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer in the world.
According to Barcelona Clinic Liver Cancer modified criteria, patients with early stage …
According to Barcelona Clinic Liver Cancer modified criteria, patients with early stage …
Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment
G Ranieri, I Marech, V Lorusso, V Goffredo… - World Journal of …, 2014 - wjgnet.com
Figure 1 Fundamental pathways involved in development of hepatocellular cancer and their
molecular targeting agents. VEGF: Vascular endothelial growth factor; PDGF: Platelet …
molecular targeting agents. VEGF: Vascular endothelial growth factor; PDGF: Platelet …
Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment.
G Ranieri, I Marech, V Lorusso, V Goffredo… - World Journal of …, 2014 - europepmc.org
Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer in the world.
According to Barcelona Clinic Liver Cancer modified criteria, patients with early stage …
According to Barcelona Clinic Liver Cancer modified criteria, patients with early stage …